Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1072517 | 0.79 | ALDH1A1 (0.41) | ALDH1A1HPGDKDM4EGLAGAA | |
| SCHEMBL1260528 | 0.77 | USP30 (0.33) | GPR119USP30HSD11B1 | |
| SCHEMBL3305629 | 0.77 | ADRB2 (0.35) | ALDH1A1KDM4EMAPTGPR119 | |
| SCHEMBL1260137 | 0.76 | CNR2 (0.32) | KDM4E | |
| SCHEMBL2439748 | 0.76 | USP30 (0.47) | GPR119USP30 | |
| SCHEMBL12892970 | 0.74 | P2RX3 (0.44) | — | |
| SCHEMBL76722 | 0.74 | NR1H2 (0.36) | — | |
| SCHEMBL3302407 | 0.72 | GPR119 (0.36) | KDM4EGPR119 | |
| SCHEMBL1260709 | 0.72 | HSD11B1 (0.35) | GPR119USP30HSD11B1 | |
| SCHEMBL2059484 | 0.72 | HSD11B1 (0.40) | MAPTUSP30HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046161-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046161-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | ALDH1A1 1199/4885HPGD 1870/4885KDM4E 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.